| Protein Name: | Cellular retinoic acid-binding protein 1 (P29762) |
|---|---|
| Gene Name: | CRABP1 |
| Description: | Cellular retinoic acid-binding protein 1 (Cellular retinoic acid- binding protein I) (CRABP-I) (Retinoic acid-binding protein I, cellular) |
| PDB ID: | |
| Protein Family: | |
| Protein Category: | Auxiliary transport protein |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| HIV-1 protease-inhibitor | Central Adiposity | Protease inhibitors inhibit CRABP-1-modified@ and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid@ a key activator of the retinoid X receptor@which leads to central adiposity. [ ADR Type 1 ] | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance |
| HIV-1 protease-inhibitor | Hyperlipidaemia | Protease inhibitors inhibit CRABP-1-modified@ and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid@ a key activator of the retinoid X receptor@which leads to hyperlipidaemia [ ADR Type 1 ] | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance |
| HIV-1 protease-inhibitor | Insulin Resistance | Protease inhibitors inhibit CRABP-1-modified@ and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid@ a key activator of the retinoid X receptor@which leads to insulin resistance [ ADR Type 1 ] | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance |
| HIV-1 protease-inhibitor | Peripheral Fat Wasting (Lipodystrophy) | Protease inhibitors inhibit CRABP-1-modified@ and cytochrome P450 3A-mediated synthesis of cis-9-retinoic acid@ a key activator of the retinoid X receptor@which leads to peripheral fat wasting (lipodystrophy) [ ADR Type 1 ] | Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance |
This panel provides information on drug category
| Toxicity | Source |
|---|